Kiwi cancer patients have been at the forefront of an international trial that may revolutionise melanoma treatment.

Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran…

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna…

Merck and Moderna’s personalized mRNA cancer vaccine helps prevent melanoma recurrence and spread, raising hopes for use against other cancers.